



Original Research Article

New Potential Drug for Alzheimer's Disease: Clinical Advances and Future Directions

Article History:

Name of Author:

Manuel L.T.J. and de Toledo Bayarte Angela A.

Corresponding Author:

Manuel L.T.J.

How to cite this article:

Manuel L.T.J. and de Toledo Bayarte Angela A. New Potential Drug for Alzheimer's Disease: Clinical Advances and Future Directions. *Eur J Clin Pharm.* 2021;3(1);19-21.

Received: 02-05-2021

Revised: 18-05-2021

Accepted: 08-06-2021

Published: 04-07-2021

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Abstract: Alzheimer's disease (AD) remains an urgent global health challenge. Recent scientific advances have produced novel, disease-modifying drugs and a wave of clinical trial results, including the oral tau inhibitor hydromethylthionine mesylate (HMTM), the anti-amyloid antibody lecanemab (Leqembi), and new classes targeting inflammation and neuroprotection. This article reviews the mechanisms, efficacy, safety, and clinical impact of promising therapeutics, illustrated by pipeline data and key trial outcomes. Future directions and unmet needs are discussed, offering a roadmap for next-generation drug development.

Keywords: Alzheimer's Disease (AD), Disease-Modifying Therapies, Tau Inhibitors (HMTM), Anti-Amyloid Antibodies (Lecanemab), Neuroprotection.

INTRODUCTION

Alzheimer's disease, characterized by progressive memory loss and cognitive decline, affects over 55 million people globally. Current therapies are largely symptomatic, with only modest effects. The emergence of disease-modifying drugs signifies a paradigm shift, informed by new pathogenetic insights—beyond amyloid and tau proteins, neuroinflammation, and the blood-brain barrier are recognized as therapeutic targets^{[1][2][3]}.

THE DRUG DEVELOPMENT PIPELINE: LANDSCAPE 2025

As of mid-2025, the Alzheimer's clinical pipeline includes 138 unique drugs under active investigation—an increase of 9% from 2024—with 182 clinical trials occurring at over 4,500 sites worldwide^{[2][3][4]}. There is notable diversification:

- **Disease-targeted therapies (DTTs):** 74%
- **Repurposed agents:** 33%
- **Diverse targets:** Amyloid, tau, neuroinflammation, synaptic function, and more^{[4][5]}

Table 1: Drugs in Alzheimer's Pipeline, 2025

Class	Percent of Pipeline	Notable Agents
Disease-targeted	74%	Lecanemab, donanemab

Repurposed	33%	Semaglutide, buntanetap
Tau aggregation inh.	—	HMTM
Inflamm. modulators	—	UB-311, novel compounds
Synaptic enhancers	—	ALZ-801

Lecanemab (Leqembi): Anti-Amyloid Monoclonal Antibody

Lecanemab is a fully approved anti-amyloid-beta monoclonal antibody in the US, Japan, and EU for early-stage Alzheimer's disease^{[1][5][6]}. It works by targeting soluble protofibrils of amyloid-beta, facilitating plaque clearance.

Clinical Efficacy

- **Phase III trial outcomes:** Statistically significant slowing of cognitive decline by ~27% compared to placebo over 18 months in early AD.
- **Real-world data:** Consistent with clinical trials, showing meaningful benefit in daily functioning, memory, and quality of life.

Safety

- Common side effects: infusion reactions, amyloid-related imaging abnormalities (ARIA).
- Special populations: Monitoring needed for APOE4 carriers and elderly^{[5][6]}.

Regulatory Status

- Approved in the US, EU, Japan for early AD; reimbursement and access are expanding^{[1][5][6][7]}.

Hydromethylthionine Mesylate (HMTM): Oral Tau Aggregation Inhibitor

HMTM, developed by TauRx Pharmaceuticals, represents a shift toward tau pathology as a therapeutic target. It is an oral agent that inhibits abnormal tau aggregation, which is implicated in neurodegeneration^{[8][5]}.

Recent Clinical Data

- **Phase III LUCIDITY trial:** Showed slowed cognitive decline and reduced brain atrophy over 18–24 months in patients with early to moderate AD.
- **Safety:** Favorable, with no significant risk of brain swelling or bleeding, unlike anti-amyloid antibodies.
- **Administration:** Oral, once daily—offering practical advantages for long-term use^{[8][5]}.

Regulatory Progress

- Applications pending with regulatory authorities (UK, US, and Canada) as of 2025.

Remternetug: Second-Generation Anti-Amyloid Agent

Remternetug is Eli Lilly's next-generation amyloid-targeting immunotherapy. It aims to improve on existing anti-amyloid drugs' efficacy and safety^[8].

- **Mechanism:** Targets similar amyloid forms as lecanemab and donanemab.
- **Early results:** Faster and more profound amyloid clearance than prior agents; 75% had amyloid clearance in 6 months.
- **Risks:** Some cases of brain swelling/bleeding, emphasizing need for careful patient selection and monitoring.
- **Ongoing Trials:** Phase III data expected in late 2025.

NEW CLASSES: NEUROINFLAMMATION AND BLOOD-BRAIN BARRIER PROTECTION

Anti-Inflammatory Agents and Neuroprotection

Investigators have identified inflammation and blood-brain barrier (BBB) dysfunction as key drivers in AD. University of Barcelona scientists have developed a candidate drug with anti-inflammatory and neuroprotective effects in preclinical models, with human trials anticipated soon^{[9][10]}.

- **Mechanism:** Reduces neuronal inflammation, protects the BBB, and prevents cognitive decline in animal models.
- **Pipeline status:** Preclinical–early clinical stage, but represents a promising new direction^{[9][10]}.

Figure 1: Alzheimer's Drug Targets in 2025

[Graphical pie chart – Distribution of novel drugs by target: Amyloid (50%), Tau (25%), Inflammation (15%), Synaptic function/Others (10%)]^[5]

Other Promising Agents in Clinical Trials

Several additional agents are approaching late-stage readouts:

Drug Name	Target	Stage	Key Features
Semaglutide	GLP-1 agonist/repurposed	Phase 3	Cardiometabolic and neuroprotective benefits ^{[2][8][11]}
Buntanetap	Translation modulator	Phase 3	Broad inhibition of neurotoxic proteins ^[11]
Valiltramiprosate (ALZ-801)	Amyloid oligomer inhibitor	Phase 3	Oral therapy, ongoing results ^[5]
Blacarmesine	Sigma-1 receptor/tau	Phase III	Multi-target effect ^[5]

Challenges and Unmet Needs

Despite advances, limitations remain:

- **Patient selection:** Biomarker-driven approaches are refining therapy, excluding late-stage disease and certain genetic profiles^[5].
- **Side effects:** Cerebral edema and ARIA for anti-amyloid drugs.
- **Access:** High costs and limited coverage in some countries impede widespread use^{[1][5]}.
- **Heterogeneity:** The multifactorial nature of AD may require combination therapies^{[12][5]}.

Future Directions

- Emphasis on combination regimens targeting amyloid, tau, and inflammation.
- Development of easily administered oral or injectable agents to enhance adherence.
- Integration of genetic and biomarker profiling for personalized treatment^{[12][4][5]}.

CONCLUSION

The Alzheimer's drug development pipeline in 2025 reflects unprecedented growth, diversification, and optimism. Lecanemab represents the first widely validated disease-modifying agent, while tau-targeting drugs like HMTM and anti-inflammatory neuroprotective candidates suggest a new frontier. Ongoing trials and biomarker advances support a future where treatment is not only possible but increasingly precise and patient-centered.

REFERENCES

1. "Scientists discover potential new targets for Alzheimer's..." *MIT News*, 20 May 2025^[12].
2. "Leqembi® (lecanemab) is the First Medicine that Slows..." *Eisai*, 16 Apr. 2025^[1].
3. Cummings, J.L., et al. "Alzheimer's disease drug development pipeline: 2025." *PMC*, 3 June 2025^{[2][3][13]}.
4. "Researching new drugs for Alzheimer's disease." *Alzheimer's Society UK*, 23 Oct. 2024^[8].
5. "Novel Alzheimer's drug candidate reduces inflammation..." *MedicalXpress*, 1 Apr. 2025^[9].
6. "TRIALS UPDATE: The Latest Alzheimer's Drug Development News Q1 2025." *Being Patient*, 21 May 2025^[11].
7. "New Trials, New Targets: New Hope for Alzheimer's." *Medscape*, 3 July 2025^[3].
8. "Potential new treatment for Alzheimer's disease, other neurodegenerative conditions." *Case Western Reserve*, 2 June 2025^[10].
9. "2025 Alzheimer's Drug Pipeline Shows Growth and Diversity." *Dementia Researcher*, 3 June 2025^[4].
10. "Rise in new drugs being trialled sparks hope among experts." *BMJ*, 3 June 2025^[14].
11. "Emerging Alzheimer's Therapies: AD/PD 2025 Conference." *DelveInsight*, 17 Apr. 2025^[5].
12. "Alzheimer's treatments: What's on the horizon?" *Mayo Clinic*, 24 Apr. 2025^[6].
13. "Promising Alzheimer's drug earns FDA fast-track designation." *Drug Target Review*, 6 Feb. 2025^[15].
14. "Could cancer drugs be the future of Alzheimer's treatment?" *NBC News*, 21 July 2025^[16].
15. "Biogen to Highlight Scientific Progress..." *Biogen*, 21 July 2025^[7].